-+ 0.00%
-+ 0.00%
-+ 0.00%

Vaximm, OSR Health unit, plans journal submission of VXM01 glioblastoma trial data

PUBT·08/03/2026 13:03:47
Listen to the news
Vaximm, OSR Health unit, plans journal submission of VXM01 glioblastoma trial data
  • OSR Holdings’ subsidiary Vaximm completed analysis from two VXM01 trials in recurrent glioblastoma, plans peer-reviewed submission in coming months.
  • Vaximm flagged encouraging cross-indication results, with top-line updates expected soon on VXM01’s development path.
  • VXM01 was reported safe and well tolerated as monotherapy or in combination, with no dose-limiting toxicities or high-grade treatment-related events.
  • Analyses showed immune activation against VEGFR-2, with dose-dependent signals and biomarker support consistent with the proposed mechanism.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608030902ACCESSWRNAPR_____1200386) on August 03, 2026, and is solely responsible for the information contained therein.